<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">STAR Protoc</journal-id><journal-id journal-id-type="iso-abbrev">STAR Protoc</journal-id><journal-title-group><journal-title>STAR Protocols</journal-title></journal-title-group><issn pub-type="epub">2666-1667</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">PMC9440594</article-id><article-id pub-id-type="pii">S2666-1667(22)00533-0</article-id><article-id pub-id-type="doi">10.1016/j.xpro.2022.101653</article-id><article-id pub-id-type="publisher-id">101653</article-id><article-categories><subj-group subj-group-type="heading"><subject>Protocol</subject></subj-group></article-categories><title-group><article-title>Protocol to assess the tolerogenic properties of adoptively transferred dendritic cells during murine experimental autoimmune encephalomyelitis</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Vogel</surname><given-names>Andrea</given-names></name><email>andrea.vogel@meduniwien.ac.at</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="fn1" ref-type="fn">3</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Kerndl</surname><given-names>Martina</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Schabbauer</surname><given-names>Gernot</given-names></name><email>gernot.schabbauer@meduniwien.ac.at</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="cor2" ref-type="corresp">&#x02217;&#x02217;</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Sharif</surname><given-names>Omar</given-names></name><email>omar.sharif@meduniwien.ac.at</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="fn2" ref-type="fn">4</xref><xref rid="cor3" ref-type="corresp">&#x02217;&#x02217;&#x02217;</xref></contrib><aff id="aff1"><label>1</label>Institute for Vascular Biology, Centre for Physiology and Pharmacology, Medical University Vienna, 1090 Vienna, Austria</aff><aff id="aff2"><label>2</label>Christian Doppler Laboratory for Arginine Metabolism in Rheumatoid Arthritis and Multiple Sclerosis, Vienna, Austria</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author <email>andrea.vogel@meduniwien.ac.at</email></corresp><corresp id="cor2"><label>&#x02217;&#x02217;</label>Corresponding author <email>gernot.schabbauer@meduniwien.ac.at</email></corresp><corresp id="cor3"><label>&#x02217;&#x02217;&#x02217;</label>Corresponding author <email>omar.sharif@meduniwien.ac.at</email></corresp><fn id="fn1"><label>3</label><p id="ntpara0010">Technical contact</p></fn><fn id="fn2"><label>4</label><p id="ntpara0015">Lead contact</p></fn></author-notes><pub-date pub-type="pmc-release"><day>26</day><month>8</month><year>2022</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><day>16</day><month>9</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>26</day><month>8</month><year>2022</year></pub-date><volume>3</volume><issue>3</issue><elocation-id>101653</elocation-id><permissions><copyright-statement>&#x000a9; 2022 The Authors</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract id="abs0010"><title>Summary</title><p>By their capacity to induce peripheral T&#x000a0;cell tolerance, dendritic cells (DCs) present a promising target cell and therapeutic strategy for treatment of several autoimmune diseases including multiple sclerosis (MS). This protocol describes how to determine the tolerogenic capacities of DCs in the context of the murine MS model, experimental autoimmune encephalomyelitis (EAE). We provide a step-by-step instruction for EAE induction, antigen-loaded bone-marrow-derived-DC (BM-DC) generation, adoptive cell transfer, and analysis of DC-mediated changes in regulatory T&#x000a0;cell populations.</p><p>For complete details on the use and execution of this protocol, please refer to <xref rid="bib7" ref-type="bibr">Vogel et&#x000a0;al. (2022)</xref>.</p></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical abstract</title><fig id="undfig1" position="anchor"><graphic xlink:href="fx1"/></fig></abstract><abstract abstract-type="author-highlights" id="abs0020"><title>Highlights</title><p><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#x02022;</label><p id="p0010">Protocol to induce EAE in mice and score for disease phenotypes</p></list-item><list-item id="u0015"><label>&#x02022;</label><p id="p0015">Generation and adoptive transfer of MOG<sub>35-55</sub>-loaded BM-DCs</p></list-item><list-item id="u0020"><label>&#x02022;</label><p id="p0020">Protocol to assess the tolerogenic properties of transferred DCs</p></list-item><list-item id="u0025"><label>&#x02022;</label><p id="p0025">Flow cytometric analysis of Tregs in secondary lymphoid organs</p></list-item></list></p></abstract><abstract abstract-type="editor-highlights" id="abs0025"><p>Publisher&#x02019;s note: Undertaking any experimental protocol requires adherence to local institutional guidelines for laboratory safety and ethics.</p></abstract><abstract abstract-type="teaser" id="abs0030"><p>By their capacity to induce peripheral T&#x000a0;cell tolerance, dendritic cells (DCs) present a promising target cell and therapeutic strategy for treatment of several autoimmune diseases including multiple sclerosis (MS). This protocol describes how to determine the tolerogenic capacities of DCs in the context of the murine MS model, experimental autoimmune encephalomyelitis (EAE). We provide a step-by-step instruction for EAE induction, antigen-loaded bone-marrow-derived-DC (BM-DC) generation, adoptive cell transfer, and analysis of DC-mediated changes in regulatory T&#x000a0;cell populations.</p></abstract><kwd-group id="kwrds0010"><title>Subject areas</title><kwd>Cell biology</kwd><kwd>Cell culture</kwd><kwd>Cell isolation</kwd><kwd>Flow cytometry/Mass cytometry</kwd><kwd>Immunology</kwd><kwd>Model organisms</kwd></kwd-group></article-meta></front><body><sec id="sec1"><title>Before you begin</title><p id="p0035">The protocol below describes the specific steps for the induction of EAE in mice and the subsequent generation and transfer of antigen-loaded tolerogenic BM-DCs. We further provide a practical guide in how to isolate and analyze cells in secondary lymphoid organs upon BM-DC transfer, with a special focus on regulatory T-cells. Although protocols exist for EAE (<xref rid="bib3" ref-type="bibr">Croxford et&#x000a0;al., 2011</xref>), this specific protocol described here, concerns how to assess the <italic>in vivo</italic> tolerogenic properties of DCs in the context of EAE.</p><p id="p0040">Before starting, we recommend establishing the EAE model in advance and just after that performing the actual BM-DC transfer experiment. This protocol requires a time schedule encompassing matching up time-points for BM-DC differentiation, EAE induction, adoptive transfers, and termination days. We suggest scheduling the different experimental steps according to the following scheme (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>).<fig id="fig1"><label>Figure&#x000a0;1</label><caption><p>Experimental scheme and timeline of EAE induction, BM-DC differentiation, and adoptive BM-DC transfers</p></caption><graphic xlink:href="gr1"/></fig></p><sec id="sec1.1"><title>Institutional permissions</title><p id="p0045">Prior to performing this protocol, the described animal studies must be approved by an institutional or national committee. All experimental procedures in this study were approved by the Austrian Ministry of Sciences (BMBWF-66.009/0265-V/3b/2019) and were conducted in strict accordance with Austrian law and FELASA guidelines.</p></sec><sec id="sec1.2"><title>Mice</title><p id="p0050">The MOG<sub>35&#x02013;55</sub> EAE is an established murine disease model for C57BL/6 mice (<xref rid="bib3" ref-type="bibr">Croxford et&#x000a0;al., 2011</xref>). We recommend inducing EAE in 7&#x02013;10 mice per experimental group, which are 8&#x02013;12&#x000a0;week old. According to various reports and our own experience, the EAE model exhibits clear sex specific differences. Female mice display increased demyelination and spinal cord infiltrating immune cells while male animals exhibit a stronger pro-inflammatory response of immune cells but also increased frequencies of regulatory cells (<xref rid="bib8" ref-type="bibr">Wiedrick et&#x000a0;al., 2021</xref>). Notably, sex hormones including estrogen are highly protective against EAE and thereby distinct female estrous phases influence EAE development (<xref rid="bib6" ref-type="bibr">Rahn et&#x000a0;al., 2014</xref>; <xref rid="bib2" ref-type="bibr">Benedek et&#x000a0;al., 2016</xref>). We noticed that in our experimental room female mice exhibit increased inter-mouse variance in EAE clinical course due to non-synchronized estrous phases and therefore usually use male animals. We suggest to include animals of both sexes in the set-up experiment to determine which gender shows more consistent EAE development.</p></sec><sec id="sec1.3"><title>Prepare complete Freud&#x02019;s adjuvants (CFA)</title><p id="p0055">
<disp-quote><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 5&#x000a0;min</bold></p></disp-quote>
<list list-type="simple" id="olist0010"><list-item id="o0010"><label>1.</label><p id="p0060">Add one vial (100&#x000a0;mg) of <italic>Mycobacterium tuberculosis</italic> H37Ra into one vial (10&#x000a0;mL) of Incomplete Freund&#x02019;s adjuvant (IFA).</p></list-item><list-item id="o0015"><label>2.</label><p id="p0065">Thoroughly mix by vortexing for 5 s.</p></list-item><list-item id="o0020"><label>3.</label><p id="p0070">Store CFA stock at 4&#x000b0;C for further use.</p></list-item></list>
</p></sec><sec id="sec1.4"><title>Prepare MOG<sub>35&#x02013;55</sub> injection emulsion</title><p id="p0075">
<disp-quote><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 20&#x02013;30&#x000a0;min</bold></p></disp-quote>
<list list-type="simple" id="olist0015"><list-item id="o0025"><label>4.</label><p id="p0080">Upon arrival of MOG<sub>35&#x02013;55,</sub> reconstitute the powder with sterile ddH<sub>2</sub>O to a stock concentration of 1&#x000a0;mg/mL and freeze aliquots at &#x02212;20&#x000b0;C. We typically prepare 1&#x000a0;mL and 500&#x000a0;&#x003bc;L aliquots. Store MOG<sub>35&#x02013;55</sub> aliquots at &#x02212;20&#x000b0;C for up to 1 year.</p></list-item><list-item id="o0030"><label>5.</label><p id="p0085">Calculate total volume of injection solution needed (150&#x000a0;&#x003bc;L per mouse) according to table in <xref rid="sec2" ref-type="sec">materials and equipment</xref>.</p></list-item><list-item id="o0035"><label>6.</label><p id="p0090">Increase calculated volume by at least 30% (needed for dead volume of syringe and loss during needle drawing).</p></list-item><list-item id="o0040"><label>7.</label><p id="p0095">Emulsify MOG<sub>35&#x02013;55</sub> and CFA by sonication until the solution turns white and viscous (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>) (We usually do 3 cycles, 10 sec with 70% power).<fig id="fig2"><label>Figure&#x000a0;2</label><caption><p>Preparation of the MOG/CFA emulsion</p></caption><graphic xlink:href="gr2"/></fig></p></list-item></list>
<disp-quote><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> During sonication ensure MOG solution does not overheat by keeping it on ice or taking breaks between cycles.</p></disp-quote>
<disp-quote><p><bold><italic>Note:</italic></bold> Emulsion cannot be stored and should always be used fresh.</p></disp-quote>
<disp-quote><p><bold><italic>Alternatives:</italic></bold> Alternatively, emulsify MOG<sub>35&#x02013;55</sub>/CFA with a 20-gauge needle/syringe by aspirating the solution up and down 30&#x02013;50 times.</p></disp-quote>
<list list-type="simple" id="olist0020"><list-item id="o0045"><label>8.</label><p id="p0100">Draw MOG<sub>35&#x02013;55</sub>/CFA emulsion into a 1&#x000a0;mL syringe.</p></list-item></list>
<disp-quote><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> Keep MOG<sub>35&#x02013;55</sub> injection solution and filled syringes always on ice.</p></disp-quote>
</p></sec><sec id="sec1.5"><title>Prepare pertussis injection solution</title><p id="p0105">
<disp-quote><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 5&#x000a0;min</bold></p></disp-quote>
<list list-type="simple" id="olist0025"><list-item id="o0050"><label>9.</label><p id="p0110">Upon arrival dissolve lyophilized pertussis toxin in sterile PBS to a stock concentration of 100&#x000a0;&#x003bc;g/mL.</p></list-item><list-item id="o0055"><label>10.</label><p id="p0115">Store reconstituted stock solution at 4&#x000b0;C for up to 6&#x000a0;months.</p></list-item></list>
<disp-quote><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> Pertussis activity can be highly variable from lot to lot. Activity and concentration for an effective EAE should be assessed prior to the experiment.</p></disp-quote>
<disp-quote><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> Always prepare pertussis injection solution freshly and directly use for injections.</p></disp-quote>
</p></sec><sec id="sec1.6"><title>Prepare erythrocyte-lysis buffer</title><p id="p0120">
<disp-quote><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 10&#x000a0;min</bold></p></disp-quote>
<list list-type="simple" id="olist0030"><list-item id="o0060"><label>11.</label><p id="p0125">Dissolve chemicals in ddH<sub>2</sub>O as indicated in the Erythrocyte-Lysis buffer table in <xref rid="sec2" ref-type="sec">materials and equipment</xref>.</p></list-item><list-item id="o0065"><label>12.</label><p id="p0130">Adjust pH to 7.2&#x02013;7.4 with HCl.</p></list-item><list-item id="o0070"><label>13.</label><p id="p0135">Sterile filter solution and store at 4&#x000b0;C in the fridge.</p></list-item></list>
</p></sec></sec><sec id="sec9"><title>Key resources table</title><p id="p0920">
<table-wrap position="float" id="undtbl7"><table frame="hsides" rules="groups"><thead><tr><th>REAGENT or RESOURCE</th><th>SOURCE</th><th>IDENTIFIER</th></tr></thead><tbody><tr><td colspan="3"><bold>Antibodies</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>Anti-mouse CD11c-PC5.5 (Clone N418)</td><td>Thermo Fisher Scientific</td><td>Cat# 35-0114-82, RRID: <ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_469709" id="intref0015">AB_469709</ext-link>)</td></tr><tr><td>Anti-mouse CD45.2-BV650 (Clone 104)</td><td>BioLegend</td><td>Cat# 109835, RRID: <ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_11203374" id="intref0020">AB_11203374</ext-link></td></tr><tr><td>Anti-mouse CD80-PE (Clone 16-10A1)</td><td>BioLegend</td><td>Cat# 104707, RRID: <ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_313128" id="intref0025">AB_313128</ext-link></td></tr><tr><td>Anti-mouse MHC Class II (I-A/I-E)-eF450 (Clone M5/114.15.2)</td><td>Thermo Fisher Scientific</td><td>Cat# 48-5321-82, RRID: <ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_1272204" id="intref0030">AB_1272204</ext-link></td></tr><tr><td>Anti-mouse CD86-FITC (Clone GL-1)</td><td>BioLegend</td><td>Cat# 105005, RRID: <ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_313148" id="intref0035">AB_313148</ext-link></td></tr><tr><td>Anti-mouse CD3e-redFluor710 (Clone 17A2)</td><td>Tonbo Biosciences</td><td>Cat# 80-0032, RRID: <ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_2621971" id="intref0040">AB_2621971</ext-link></td></tr><tr><td>Anti-mouse CD25-BV421 (Clone PC61)</td><td>BioLegend</td><td>Cat# 102033, RRID: <ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_10895908" id="intref0045">AB_10895908</ext-link></td></tr><tr><td>Anti-mouse CD8a-BV510 (Clone 53-6.7)</td><td>BioLegend</td><td>Cat# 100752, RRID: <ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_2563057" id="intref0050">AB_2563057</ext-link></td></tr><tr><td>Anti-mouse CD4-PerCP-Cy5.5 (Clone GK1)</td><td>BioLegend</td><td>Cat# 100433, RRID: <ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_893330" id="intref0055">AB_893330</ext-link></td></tr><tr><td>Anti-mouse FoxP3-APC (Clone 3G3)</td><td>Tonbo Biosciences</td><td>Cat# 20-5773, RRID: <ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_2621604" id="intref0060">AB_2621604</ext-link></td></tr><tr><td>Mouse IgG1 kappa-APC (Clone MOPC-21)</td><td>BioLegend</td><td>Cat# 981806</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Chemicals, peptides, and recombinant proteins</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>Myelin oligodendrocyte glycoprotein (MOG)<sub>35&#x02013;55</sub></td><td>Charit&#x000e8; Berlin</td><td>NA</td></tr><tr><td>Incomplete Freund&#x02019;s adjuvant</td><td>Sigma-Aldrich</td><td>Cat# F5506</td></tr><tr><td>Mycobacterium tuberculosis H37Ra</td><td>BD</td><td>Cat# 231141</td></tr><tr><td>Pertussis toxin</td><td>List Biological Laboratories</td><td>Cat# 181</td></tr><tr><td>recombinant murine GM-CSF</td><td>R&#x00026;D</td><td>Cat# 415-ML-050</td></tr><tr><td>recombinant murine IL-4</td><td>Miltenyi Biotec</td><td>Cat# 130-097-761</td></tr><tr><td>Fixable Viability Dye eFluor&#x02122; 780</td><td>Thermo Fisher Scientific</td><td>Cat# 65-0865-14</td></tr><tr><td>FoxP3/Transcription factor staining buffer set</td><td>Thermo Fisher Scientific</td><td>Cat# 00-5523-00</td></tr><tr><td>eBioscience Fixation Buffer</td><td>Thermo Fisher Scientific</td><td>Cat# 00-8222-49</td></tr><tr><td>IMDM, 500&#x000a0;mL</td><td>Thermo Fisher Scientific</td><td>Cat# 12440061</td></tr><tr><td>MEM Non-Essential Amino Acids Solution 10&#x000a0;mM (100&#x000d7;)</td><td>Thermo Fisher Scientific</td><td>Cat# 11140050</td></tr><tr><td>2-Mercaptoethanol, 50&#x000a0;mM (1000&#x000d7;)</td><td>Thermo Fisher Scientific</td><td>Cat# 31350010</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Experimental models: Organisms/strains</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>Mouse:C57BL/6J (8&#x02013;12&#x000a0;week old, male)</td><td>Charles River</td><td>RRID: IMSR_JAX:000664</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3">Software</td></tr><tr><td>FlowJo v10</td><td>FlowJo LLC</td><td><ext-link ext-link-type="uri" xlink:href="https://www.flowjo.com" id="intref0065">https://www.flowjo.com</ext-link></td></tr><tr><td>CytExpert v2.4</td><td>Beckman Coulter</td><td><ext-link ext-link-type="uri" xlink:href="https://www.beckman.at/flow-cytometry/instruments/cytoflex/software" id="intref0070">https://www.beckman.at/flow-cytometry/instruments/cytoflex/software</ext-link></td></tr><tr><td>Prism v.9</td><td>GraphPad</td><td><ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/scientific-software/prism/" id="intref0075">https://www.graphpad.com/scientific-software/prism/</ext-link></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Other</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>Restrainer (TAILVEINER&#x000ae;)</td><td>2Biological Instruments</td><td>Cat# TV 150, small</td></tr><tr><td>Sonicator BANDELIN SONOPULS</td><td>BANDELIN</td><td>Cat# BASO_17007</td></tr><tr><td>Cytoflex S</td><td>Beckman Coulter</td><td>Product #C01161</td></tr></tbody></table></table-wrap>
</p></sec><sec id="sec2"><title>Materials and equipment</title><p id="p0140">
<table-wrap position="float" id="undtbl1"><caption><p>MOG<sub>35&#x02013;55</sub> injection solution (per mouse)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Stock concentration</th><th>Dilution</th><th>Amount</th></tr></thead><tbody><tr><td>MOG<sub>35&#x02013;55</sub></td><td>1&#x000a0;mg/mL</td><td>1:2</td><td>75&#x000a0;&#x003bc;L</td></tr><tr><td>CFA</td><td>N/A</td><td>1:2</td><td>75&#x000a0;&#x003bc;L</td></tr><tr><td><bold>Total</bold></td><td><bold>N/A</bold></td><td><bold>N/A</bold></td><td><bold>150&#x000a0;&#x003bc;L</bold></td></tr></tbody></table><table-wrap-foot><fn><p>Store MOG aliquots at &#x02212;20&#x000b0;C for up to 1 year.</p></fn></table-wrap-foot></table-wrap>
<disp-quote><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> Always use freshly thawed MOG aliquots to prepare the injection solution and avoid repeated freeze/thaw cycles. Always freshly prepare the injection solution and keep on ice during preparation.</p></disp-quote>
<table-wrap position="float" id="undtbl2"><caption><p>Pertussis injection solution (per mouse)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Stock concentration</th><th>Final concentration</th><th>Amount</th></tr></thead><tbody><tr><td>Pertussis</td><td>100&#x000a0;&#x003bc;g/mL</td><td>2&#x000a0;&#x003bc;g/mL</td><td>2&#x000a0;&#x003bc;L</td></tr><tr><td>PBS</td><td>N/A</td><td>N/A</td><td>98&#x000a0;&#x003bc;L</td></tr><tr><td><bold>Total</bold></td><td><bold>N/A</bold></td><td><bold>N/A</bold></td><td><bold>100&#x000a0;&#x003bc;L</bold></td></tr></tbody></table><table-wrap-foot><fn><p>Store reconstituted pertussis stock solution at 4&#x000b0;C for up to 6&#x000a0;months.</p></fn></table-wrap-foot></table-wrap>
<table-wrap position="float" id="undtbl3"><caption><p>Erythrocyte-lysis buffer</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Final concentration</th><th>Amount</th></tr></thead><tbody><tr><td>NH<sub>4</sub>Cl</td><td>0.15 M</td><td>8.024 g</td></tr><tr><td>KHCO<sub>3</sub></td><td>10&#x000a0;mM</td><td>1 g</td></tr><tr><td>Na<sub>2</sub>EDTA</td><td>0.1&#x000a0;mM</td><td>37.2&#x000a0;mg</td></tr><tr><td><bold>Total</bold></td><td><bold>N/A</bold></td><td><bold>1,000&#x000a0;mL</bold></td></tr></tbody></table><table-wrap-foot><fn><p>Store at 4&#x000b0;C for up to 1 year.</p></fn></table-wrap-foot></table-wrap>
<disp-quote><p><bold><italic>Alternatives:</italic></bold> Alternatively, commercially available red blood cell lysis buffers can be used (eg. eBioscience&#x02122; 1&#x000d7; RBC Lysis Buffer, Cat# 00-4333-57).</p></disp-quote>
<table-wrap position="float" id="undtbl4"><caption><p>Culture medium</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Stock concentration</th><th>Final concentration</th><th>Amount</th></tr></thead><tbody><tr><td>IMDM medium</td><td>N/A</td><td>N/A</td><td>430&#x000a0;mL</td></tr><tr><td>Fetal bovine serum (FBS)</td><td>N/A</td><td>10% (v/v)</td><td>50&#x000a0;mL</td></tr><tr><td>Penicillin/Streptomycin</td><td>100&#x000d7;</td><td>1% (v/v)</td><td>5&#x000a0;mL</td></tr><tr><td>non-essential amino acids</td><td>100&#x000d7;</td><td>1% (v/v)</td><td>5&#x000a0;mL</td></tr><tr><td>2-mercaptoethanol</td><td>50&#x000a0;mM</td><td>50&#x000a0;&#x003bc;M</td><td>500&#x000a0;&#x003bc;L</td></tr><tr><td><bold>Total</bold></td><td><bold>N/A</bold></td><td><bold>N/A</bold></td><td><bold>500&#x000a0;mL</bold></td></tr></tbody></table></table-wrap>
<disp-quote><p><bold><italic>Alternatives:</italic></bold> Alternatively, DC differentiation can also be performed using RPMI or DMEM as culture medium if necessary.</p></disp-quote>
<table-wrap position="float" id="undtbl5"><caption><p>FACS Antibody Staining mix</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Antibody</th><th>Dilution</th></tr></thead><tbody><tr><td/><td>Fixable Viability Dye eFluor&#x02122; 780</td><td>1:2,000</td></tr><tr><td rowspan="5">Quality Control of DCs</td><td>CD11c-PC5.5</td><td>1:80</td></tr><tr><td>CD45.2-BV650</td><td>1:100</td></tr><tr><td>CD80-PE</td><td>1:80</td></tr><tr><td>MHC Class II (I-A/I-E)-eF450</td><td>1:100</td></tr><tr><td>CD86-FITC</td><td>1:80</td></tr><tr><td rowspan="8">T cells</td><td colspan="2">Surface staining</td></tr><tr><td>CD3e-redFluor710</td><td>1:100</td></tr><tr><td>CD25-BV421</td><td>1:100</td></tr><tr><td>CD8a-BV510</td><td>1:100</td></tr><tr><td>CD4-PerCP-Cy5.5</td><td>1:100</td></tr><tr><td colspan="2">Intracellular staining</td></tr><tr><td>FoxP3-APC</td><td>1:160</td></tr><tr><td>IgG1 kappa-APC (FoxP3 isotype control)</td><td>1:160</td></tr></tbody></table></table-wrap>
<disp-quote><p><bold><italic>Note:</italic></bold> If different antibodies are used, determine the appropriate concentration of antibodies by titration and set up the panel and compensation matrix prior to the experiment.</p></disp-quote>
</p></sec><sec id="sec3"><title>Step-by-step method details</title><sec id="sec3.1"><title>Induction of experimental autoimmune encephalomyelitis (EAE)</title><p id="p0145">
<disp-quote><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 1&#x02013;2&#x000a0;h for EAE induction</bold></p></disp-quote>
<disp-quote><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 30&#x000a0;min&#x02013;1&#x000a0;h for Scoring (depending on mouse numbers)</bold></p></disp-quote>
<list list-type="simple" id="olist0035"><list-item id="o0075"><label>1.</label><p id="p0150">Induction of EAE.<list list-type="simple" id="olist0040"><list-item id="o0080"><label>a.</label><p id="p0155">Prepare MOG injection solution and pertussis injection solution as described earlier.</p></list-item><list-item id="o0085"><label>b.</label><p id="p0160">Restrain mouse in restrainer.</p></list-item><list-item id="o0090"><label>c.</label><p id="p0165">Locate the right flank and apply 70% ethanol with a pipet tip to wet the fur and localize the injection site (see <xref rid="mmc1" ref-type="supplementary-material">Methods video S1</xref>).</p><p id="p0170"><supplementary-material content-type="local-data" id="mmc1"><caption><title>Methods video S1. Subcutaneous injection of MOG/CFA emulsion for EAE induction, related to step 1</title></caption><media xlink:href="mmc1.mp4"/></supplementary-material></p></list-item><list-item id="o0095"><label>d.</label><p id="p0175">Subcutaneously inject mouse with 75&#x000a0;&#x003bc;L of MOG-emulsion and carefully remove the needle (see <xref rid="mmc1" ref-type="supplementary-material">Methods video S1</xref>).</p></list-item><list-item id="o0100"><label>e.</label><p id="p0180">Repeat at left flank.<disp-quote><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> Successful subcutaneous injections should result in visible bolus shaped depots under the skin. No significant amount of MOG/CFA emulsion should leak after the injection.</p></disp-quote></p></list-item><list-item id="o0105"><label>f.</label><p id="p0185">Draw pertussis injection solution in a 1&#x000a0;mL syringe.</p></list-item><list-item id="o0110"><label>g.</label><p id="p0190">Inject each mouse i.p. with 100&#x000a0;&#x003bc;L.</p></list-item><list-item id="o0115"><label>h.</label><p id="p0195">2&#x000a0;days later repeat the preparation and injection of the pertussis solution.</p></list-item></list></p></list-item><list-item id="o0120"><label>2.</label><p id="p0200">EAE scoring.<list list-type="simple" id="olist0050"><list-item id="o0125"><label>a.</label><p id="p0205">Starting on day 7 post EAE induction, examine mice daily for weight loss and clinical symptoms.</p></list-item><list-item id="o0130"><label>b.</label><p id="p0210">Classify clinical symptoms according to the following criteria. See <xref rid="mmc2" ref-type="supplementary-material">Methods video S2</xref>.</p></list-item></list></p></list-item></list>
<table-wrap position="float" id="undtbl6"><caption><p>EAE scoring table</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Score</th><th>Clinical symptoms, observations</th></tr></thead><tbody><tr><td>0</td><td>No clinical symptoms, mouse is healthy.</td></tr><tr><td>0.5</td><td>Slight orientation or motoric problems during climbing. The tail shows muscle tension, but tip of the tail is limp.</td></tr><tr><td>1</td><td>Complete paralysis of the tail. When the mouse is picked up, the whole tail is loosely hanging down with no muscle tension.</td></tr><tr><td>1.5</td><td>Complete paralysis of the tail and first signs of hind leg weakness by wobbly motions.</td></tr><tr><td>2</td><td>Paralysis of one hind leg.</td></tr><tr><td>2.5</td><td>Paralysis of one hind leg and restrained movement of the second hind leg.</td></tr><tr><td>3</td><td>Paralysis of both hind legs.</td></tr><tr><td>3.5</td><td>Paralysis of both hind legs and restrained movement in one of the front legs.</td></tr><tr><td>4</td><td>Complete hind and advanced front leg paralysis. The mouse cannot move around the cage at all and does not respond to contact. Mice should be euthanized at this score and a score of 4 is entered for the rest of the experiment. Mice that are found dead in the cage also get a score of 4 for the rest of the experiment.</td></tr></tbody></table></table-wrap>
<disp-quote><p><bold><italic>Note:</italic></bold> The disease kinetics (day of onset, peak, remission phase varies between experiments, mouse strains, laboratories. However, a successful immunization regimen should result in 80%&#x02013;100% disease incidence. Typically, mice start to lose weight and develop the first symptoms within 7&#x02013;12&#x000a0;days after EAE induction (<xref rid="bib5" ref-type="bibr">Mendel et&#x000a0;al., 1995</xref>; <xref rid="bib1" ref-type="bibr">Barthelmes et&#x000a0;al., 2016</xref>). <xref rid="sec7.1" ref-type="sec">Troubleshooting 1</xref>.</p></disp-quote>
<disp-quote><p><bold><italic>Note:</italic></bold> Some mice may develop skin lesions at the injection site. Small ulcers usually heal within a few days without treatment but if necessary, mice can be treated with antibiotic ointment. However, in rare cases some mice develop larger skin lesions (approximately 2&#x000a0;cm diameter) which are characterized by complete hair loss and redness. Mice with this type of lesion rarely develop EAE symptoms and should be excluded from the experiment.</p></disp-quote>
<disp-quote><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> Provide mice with wet food and easily accessible water on the cage floor as soon as they show first signs of paralysis. If severe dehydration is observed, mice should be injected with glucose-supplemented saline or Ringer&#x02019;s solution.</p></disp-quote>
<disp-quote><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> Scoring should be done in a blinded manner and ideally always by the same person.</p></disp-quote>
</p><p id="p0215">
<supplementary-material content-type="local-data" id="mmc2"><caption><title>Methods video S2. Overview of clinical scores in EAE bearing mice, related to step 2</title></caption><media xlink:href="mmc2.mp4"/></supplementary-material>
</p></sec><sec id="sec3.2"><title>Bone marrow isolation and differentiation of bone-marrow-derived dendritic cells (BM-DCs)</title><p id="p0220">
<disp-quote><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 1&#x02013;2&#x000a0;h Bone marrow isolation</bold></p></disp-quote>
<disp-quote><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 7&#x000a0;days Differentiation</bold></p></disp-quote>
<list list-type="simple" id="olist0055"><list-item id="o0135"><label>3.</label><p id="p0225">Isolation of bones.<list list-type="simple" id="olist0060"><list-item id="o0140"><label>a.</label><p id="p0230">Humanely euthanize mice according to ethical guidelines and spray with 70% ethanol to sterilize skin.<disp-quote><p><bold><italic>Note:</italic></bold> We usually use 8&#x02013;12&#x000a0;week old mice for BM-DC generation.</p></disp-quote></p></list-item><list-item id="o0145"><label>b.</label><p id="p0235">Cut open abdominal skin with scissors and remove skin from the whole hind leg by pulling out the leg from its skin layers.</p></list-item><list-item id="o0150"><label>c.</label><p id="p0240">Dislocate the hip joint without breaking it, remove the whole hind-leg and place it in a falcon with fresh PBS.<disp-quote><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> Bones should not get broken during the isolation otherwise bone marrow cells might get contaminated.</p></disp-quote></p></list-item></list></p></list-item><list-item id="o0155"><label>4.</label><p id="p0245">Perform all following steps in a tissue culture-hood.</p></list-item><list-item id="o0160"><label>5.</label><p id="p0250">Isolation of bone marrow cells (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>).<list list-type="simple" id="olist0070"><list-item id="o0165"><label>a.</label><p id="p0255">Take hind legs out of tube and quickly dip in a falcon filled with 70% ethanol. Place bones on a sterile paper towel.</p></list-item><list-item id="o0170"><label>b.</label><p id="p0260">Remove the paw and subsequently try to remove as much muscle and connective tissue as possible.</p></list-item><list-item id="o0175"><label>c.</label><p id="p0265">Place the bones in a 6-well dish filled with sterile PBS (finish bone isolation of all mice/genotypes needed for the experiment).</p></list-item><list-item id="o0180"><label>d.</label><p id="p0270">Prepare 50&#x000a0;mL falcons and place a 70&#x000a0;&#x003bc;M cell strainer on them.</p></list-item><list-item id="o0185"><label>e.</label><p id="p0275">Pre-wet strainer with 2&#x000a0;mL of PBS.</p></list-item><list-item id="o0190"><label>f.</label><p id="p0280">Take the tibia and femur with a sterile forceps and trim both ends using sterilized scissors to open up the bones.</p></list-item><list-item id="o0195"><label>g.</label><p id="p0285">Take a 5&#x000a0;mL syringe and fill it with 5&#x000a0;mL sterile PBS and attach a 27-gauge needle to it.</p></list-item><list-item id="o0200"><label>h.</label><p id="p0290">Hold the tibia/femur over the prepared strainer, insert the needle into the narrow end of the tibia/femur.</p></list-item><list-item id="o0205"><label>i.</label><p id="p0295">Flush the bone marrow onto the 70&#x000a0;&#x003bc;M strainer.</p></list-item><list-item id="o0210"><label>j.</label><p id="p0300">Carefully disrupt bone marrow chunks with the tip of the serological pipet and wash the strainer with 10&#x000a0;mL PBS or culture medium.</p></list-item><list-item id="o0215"><label>k.</label><p id="p0305">When no more red chunks are visible on the strainer, spin down cell suspension at 500&#x000a0;g for 5&#x000a0;min at room temperature.</p></list-item><list-item id="o0220"><label>l.</label><p id="p0310">A clear red visible pellet should be visible.</p></list-item><list-item id="o0225"><label>m.</label><p id="p0315">Discard the supernatant by inverting the falcon over a waste bottle.</p></list-item><list-item id="o0230"><label>n.</label><p id="p0320">Resuspend cell pellet in 1&#x000a0;mL of erythrocyte-lysis buffer, incubate for 5&#x000a0;min at room temperature.</p></list-item><list-item id="o0235"><label>o.</label><p id="p0325">Stop erythrocyte-lysis by adding 10&#x000a0;mL of culture medium.</p></list-item><list-item id="o0240"><label>p.</label><p id="p0330">Spin down cell suspension at 500&#x000a0;g for 5&#x000a0;min at room temperature. Pellet should be completely white. In case pellet remains red, erylysis should be repeated.</p></list-item><list-item id="o0245"><label>q.</label><p id="p0335">Discard the supernatant by inverting the falcon over a waste bottle.</p></list-item><list-item id="o0250"><label>r.</label><p id="p0340">Resuspend cell pellet in 10&#x000a0;mL of culture medium and count cells.</p></list-item></list><fig id="fig3"><label>Figure&#x000a0;3</label><caption><p>Critical steps of bone marrow isolation and BM-DC differentiation</p></caption><graphic xlink:href="gr3"/></fig></p></list-item><list-item id="o0255"><label>6.</label><p id="p0345">Start BM-DC differentiation.<list list-type="simple" id="olist0075"><list-item id="o0260"><label>a.</label><p id="p0350">Seed 5&#x000a0;&#x000d7;&#x000a0;106 cells in 10&#x000a0;mL culture medium in a 10&#x000a0;cm tissue-culture treated petri-dish with 20&#x000a0;ng/mL GM-CSF and 5&#x000a0;ng/mL IL-4.</p></list-item><list-item id="o0265"><label>b.</label><p id="p0355">Put dishes in a 37&#x000b0;C, 5% CO2 incubator.</p></list-item></list></p></list-item><list-item id="o0270"><label>7.</label><p id="p0360">Day 3: Add 5&#x000a0;mL of fresh culture media with 20&#x000a0;ng/mL GM-CSF and 5&#x000a0;ng/mL IL-4. Total volume of culture media is then 15&#x000a0;mL.</p></list-item></list>
<disp-quote><p><bold><italic>Optional:</italic></bold> BM-DC generation also works from frozen bone-marrow, however in our experience the yield of fully-differentiated BM-DCs is decreased.</p></disp-quote>
</p></sec><sec id="sec3.3"><title>Harvest of fully differentiated BM-DCs and antigen loading</title><p id="p0365">
<disp-quote><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 5&#x02013;6 h</bold></p></disp-quote>
<list list-type="simple" id="olist0080"><list-item id="o0275"><label>8.</label><p id="p0370">Day 6&#x02013;7: Harvest fully differentiated BM-DCs (<xref rid="sec7.3" ref-type="sec">troubleshooting 2</xref>).<list list-type="simple" id="olist0085"><list-item id="o0280"><label>a.</label><p id="p0375">Check cell morphology and confluency under the microscope (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>A).<fig id="fig4"><label>Figure&#x000a0;4</label><caption><p>Quality control of antigen-loaded BM-DCs</p><p>(A and B) Morphology of BM-DC cultures during differentiation (A)&#x000a0;and quality control of MOG<sub>35&#x02013;55</sub> loaded BM-DCs by flow cytometry (B). Scale bars&#x000a0;= 500&#x000a0;&#x003bc;M, cells are gated for viable CD11c<sup>+</sup> DCs and further assessed for their CD80, CD86, MHC-II, and MHC-I surface expression.</p></caption><graphic xlink:href="gr4"/></fig></p></list-item><list-item id="o0285"><label>b.</label><p id="p0380">Carefully remove 6&#x000a0;mL of media directly from surface.</p></list-item><list-item id="o0290"><label>c.</label><p id="p0385">With the remaining media detach loosely attached cells by pipetting over the dish several times.<disp-quote><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> Post differentiation, do not use highly adherent cells as most of these cells do not represent mature BM-DCs (<xref rid="bib4" ref-type="bibr">Helft et&#x000a0;al., 2015</xref>).</p></disp-quote></p></list-item><list-item id="o0295"><label>d.</label><p id="p0390">Transfer cell suspension in a 15&#x000a0;mL falcon and count cells.</p></list-item></list></p></list-item><list-item id="o0300"><label>9.</label><p id="p0395">Antigen loading of BM-DCs.<list list-type="simple" id="olist0095"><list-item id="o0305"><label>a.</label><p id="p0400">Spin down cell suspension at 500&#x000a0;g for 5&#x000a0;min at room temperature and discard the supernatant.</p></list-item><list-item id="o0310"><label>b.</label><p id="p0405">Resuspend 2&#x000a0;&#x000d7;&#x000a0;106 cells in 2&#x000a0;mL culture medium per well and plate in a 6 well plate.</p></list-item><list-item id="o0315"><label>c.</label><p id="p0410">Immediately add 10&#x000a0;&#x003bc;g/mL MOG35&#x02013;55 (freshly thawed aliquot).<disp-quote><p><bold><italic>Note:</italic></bold> Always plate a little more BM-DCs than needed. Not all cells can be recovered after scraping and additional suspension is needed for the dead volume of the syringe and BM-DC quality control.</p></disp-quote></p></list-item><list-item id="o0320"><label>d.</label><p id="p0415">Incubate cells for 5&#x02013;6&#x000a0;h in a 37&#x000b0;C, 5%CO<sub>2</sub> incubator.</p></list-item></list></p></list-item></list>
</p></sec><sec id="sec3.4"><title>Transfer of antigen-loaded DCs and quality control</title><p id="p0420"><disp-quote><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 1 h</bold></p></disp-quote>This step describes adoptive transfer of antigen loaded bone-marrow derived dendritic cells and their quality control. The quantity of cell transfers and the exact timing might be adapted depending on the biological question.<list list-type="simple" id="olist0100"><list-item id="o0325"><label>10.</label><p id="p0425">Harvest of MOG-loaded BM-DCs.<list list-type="simple" id="olist0105"><list-item id="o0330"><label>a.</label><p id="p0430">Visually check cells (upon antigen loading DCs usually loosely attach to the dish) under the microscope.</p></list-item><list-item id="o0335"><label>b.</label><p id="p0435">Gently detach DCs by using a cell scraper.</p></list-item><list-item id="o0340"><label>c.</label><p id="p0440">Transfer cell suspension into a 15&#x000a0;mL falcon.</p></list-item><list-item id="o0345"><label>d.</label><p id="p0445">Determine cell number.</p></list-item><list-item id="o0350"><label>e.</label><p id="p0450">Spin down cell suspension at 500&#x000a0;g for 5&#x000a0;min at room temperature and discard the supernatant.</p></list-item><list-item id="o0355"><label>f.</label><p id="p0455">Resuspend cells in sterile PBS at a concentration of 1&#x000a0;&#x000d7;&#x000a0;107 cells/mL. You will require 50&#x000a0;&#x003bc;L per mouse plus 100&#x000a0;&#x003bc;L excess volume if syringes with dead-volume are used.</p></list-item><list-item id="o0360"><label>g.</label><p id="p0460">Transfer cell suspension in an Eppendorf tube (2&#x000a0;mL or 5&#x000a0;mL) and store cells on ice until injections. Injections should be performed immediately.</p></list-item><list-item id="o0365"><label>h.</label><p id="p0465">Keep a cell aliquot for the quality control (step 12).</p></list-item></list></p></list-item><list-item id="o0370"><label>11.</label><p id="p0470">Transfer of cells.<list list-type="simple" id="olist0110"><list-item id="o0375"><label>a.</label><p id="p0475">Randomize mice across experimental groups/conditions.</p></list-item><list-item id="o0380"><label>b.</label><p id="p0480">Anaesthetize mice with isoflurane (2%&#x02013;4% under constant oxygen flow).</p></list-item><list-item id="o0385"><label>c.</label><p id="p0485">Draw BM-DC cell suspension into a 1&#x000a0;mL syringe and mount a 27G needle.</p></list-item><list-item id="o0390"><label>d.</label><p id="p0490">Intravenously inject each mouse with 50&#x000a0;&#x003bc;L of the DC cell suspension via the retro-orbital sinusoid.</p></list-item></list></p></list-item></list><disp-quote><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> Injections should be performed as quick as possible to ensure an evenly suspended cell injection solution.</p></disp-quote><disp-quote><p><bold><italic>Note:</italic></bold> The BM-DC transfer is also compatible with the use of <italic>in vivo</italic> blocking antibodies such as anti-PD-1. We usually inject blocking antibodies i.p. 2&#x02013;4&#x000a0;h before mice receive the cell transfer. For further details please refer to (<xref rid="bib7" ref-type="bibr">Vogel et&#x000a0;al., 2022</xref>).</p></disp-quote><list list-type="simple" id="olist0115"><list-item id="o0395"><label>12.</label><p id="p0495">Quality control of transferred BM-DCs.<list list-type="simple" id="olist0120"><list-item id="o0400"><label>a.</label><p id="p0500">Transfer approximately 0.5&#x000a0;&#x000d7;&#x000a0;10<sup>6</sup> cells in a 96-well plate for staining. Alternatively, cells can also be stained in a tube.</p></list-item><list-item id="o0405"><label>b.</label><p id="p0505">Prepare the DC quality control antibody staining mix (according to table in <xref rid="sec2" ref-type="sec">materials and equipment</xref>) in 1% FCS/PBS (including viability dye).</p></list-item><list-item id="o0410"><label>c.</label><p id="p0510">Centrifuge cells at 500&#x000a0;g for 5&#x000a0;min at room temperature and discard the supernatant.</p></list-item><list-item id="o0415"><label>d.</label><p id="p0515">Resuspend cells in 10&#x000a0;&#x003bc;L staining mix and incubate for 15&#x000a0;min at RT.</p></list-item><list-item id="o0420"><label>e.</label><p id="p0520">Add 180&#x000a0;&#x003bc;L of 1% FCS/PBS and centrifuge at 500&#x000a0;g for 5&#x000a0;min at RT.</p></list-item><list-item id="o0425"><label>f.</label><p id="p0525">Discard the supernatant and resuspend pellets in 150&#x000a0;&#x003bc;L 1% FCS/PBS.<disp-quote><p><inline-graphic xlink:href="fx4.gif"/><bold>Pause point:</bold> If cells cannot be analyzed on the same day, resuspend cells in 100&#x000a0;&#x003bc;L eBioscience fixation buffer and incubate for 15&#x000a0;min at RT. Spin cells at 500&#x000a0;g for 5&#x000a0;min at room temperature, discard the supernatant and resuspend in 150&#x000a0;&#x003bc;L 1% FCS/PBS. Cells can now be stored at 4&#x000b0;C in the dark for several days.</p></disp-quote></p></list-item><list-item id="o0430"><label>g.</label><p id="p0530">Acquire samples on FACS machine.</p></list-item></list></p></list-item></list></p></sec><sec id="sec3.5"><title>Harvest and processing of spleen and lymph nodes</title><p id="p0535">
<disp-quote><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 1&#x02013;2 h</bold></p></disp-quote>
<list list-type="simple" id="olist0125"><list-item id="o0435"><label>13.</label><p id="p0540">3&#x000a0;days after the last DC-transfer (day 17 post EAE induction), euthanize mice and process spleen and lymph nodes for flow cytometric analysis.<list list-type="simple" id="olist0130"><list-item id="o0440"><label>a.</label><p id="p0545">Prepare a 6-well plate, place a 70&#x000a0;&#x003bc;m strainer in each well and fill with 3&#x000a0;mL of sterile PBS. Put plate on ice.</p></list-item><list-item id="o0445"><label>b.</label><p id="p0550">Isolate spleen and inguinal lymph nodes of each mouse and place into a separate well.</p></list-item></list></p></list-item><list-item id="o0450"><label>14.</label><p id="p0555">Spleen processing.<list list-type="simple" id="olist0140"><list-item id="o0455"><label>a.</label><p id="p0560">By using the plunger from a 5&#x000a0;mL syringe, mash the spleen through the cell strainer.</p></list-item><list-item id="o0460"><label>b.</label><p id="p0565">Wash the strainer with 5&#x000a0;mL of PBS.</p></list-item><list-item id="o0465"><label>c.</label><p id="p0570">Discard the strainer.</p></list-item><list-item id="o0470"><label>d.</label><p id="p0575">Transfer splenocyte cell suspension into a 15&#x000a0;mL falcon.</p></list-item><list-item id="o0475"><label>e.</label><p id="p0580">Centrifuge cells at 500&#x000a0;g for 5&#x000a0;min at RT.</p></list-item><list-item id="o0480"><label>f.</label><p id="p0585">Decant the supernatant and resuspend pellet in 1&#x000a0;mL of erythrocyte-lysis buffer.</p></list-item><list-item id="o0485"><label>g.</label><p id="p0590">Incubate for 5&#x000a0;min at RT.</p></list-item><list-item id="o0490"><label>h.</label><p id="p0595">Fill up falcon to 10&#x000a0;mL with PBS and spin down cells at 500&#x000a0;g for 5&#x000a0;min at RT.</p></list-item><list-item id="o0495"><label>i.</label><p id="p0600">Decant supernatant and resuspend pellet in 10&#x000a0;mL PBS.<disp-quote><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> Remove cell clumps that usually form during erythrocyte-lysis.</p></disp-quote></p></list-item><list-item id="o0500"><label>j.</label><p id="p0605">Transfer 200&#x000a0;&#x003bc;L splenocyte suspension into a 96-well plate and continue with &#x0201c;flow cytometry staining&#x0201d;.</p></list-item></list></p></list-item><list-item id="o0505"><label>15.</label><p id="p0610">Lymph node processing.<list list-type="simple" id="olist0150"><list-item id="o0510"><label>a.</label><p id="p0615">By using the plunger from a 5&#x000a0;mL syringe, mash the lymph nodes through the cell strainer.</p></list-item><list-item id="o0515"><label>b.</label><p id="p0620">Wash the strainer with 5&#x000a0;mL of PBS.</p></list-item><list-item id="o0520"><label>c.</label><p id="p0625">Discard the strainer.</p></list-item><list-item id="o0525"><label>d.</label><p id="p0630">Transfer cell suspension into a 15&#x000a0;mL falcon.</p></list-item><list-item id="o0530"><label>e.</label><p id="p0635">Centrifuge cells at 500&#x000a0;g for 5&#x000a0;min at RT.</p></list-item><list-item id="o0535"><label>f.</label><p id="p0640">Decant supernatant and resuspend pellet in 5&#x000a0;mL PBS.</p></list-item><list-item id="o0540"><label>g.</label><p id="p0645">Transfer 200&#x000a0;&#x003bc;L lymph node suspension into a 96-well plate and continue with &#x0201c;flow cytometry staining&#x0201d;.</p></list-item></list></p></list-item></list>
</p></sec><sec id="sec3.6"><title>Flow cytometry staining</title><p id="p0650">
<disp-quote><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 2&#x02013;3 h</bold></p></disp-quote>
<list list-type="simple" id="olist0155"><list-item id="o0545"><label>16.</label><p id="p0655">Prepare antibody staining mix (according to table in <xref rid="sec2" ref-type="sec">materials and equipment</xref>) in 1% FCS/PBS (including viability dye).</p></list-item></list>
<disp-quote><p><bold><italic>Note:</italic></bold> Include single staining controls for setting up a proper compensation. For critical surface markers, exhibiting gradual expression patterns such as CD25, include fluorescence minus one (FMO) controls to ensure proper gating during data analysis.</p></disp-quote>
<list list-type="simple" id="olist0160"><list-item id="o0550"><label>17.</label><p id="p0660">Centrifuge 96-well plates with spleen and lymph node cells at 500&#x000a0;g for 5&#x000a0;min at RT and discard supernatant.</p></list-item><list-item id="o0555"><label>18.</label><p id="p0665">Resuspend cells in 10&#x000a0;&#x003bc;L antibody staining mix and incubate for 15&#x000a0;min at RT in the dark.</p></list-item><list-item id="o0560"><label>19.</label><p id="p0670">Wash cells by adding 180&#x000a0;&#x003bc;L 1% FCS/PBS to each well.</p></list-item><list-item id="o0565"><label>20.</label><p id="p0675">Centrifuge plate at 500&#x000a0;g for 5&#x000a0;min at RT and discard supernatant.</p></list-item><list-item id="o0570"><label>21.</label><p id="p0680">Prepare 1&#x000d7; Fix/Perm buffer by adding 1 part Fix/Perm concentrate and 3 parts Fix/Perm Diluent from the FoxP3 Fix/Perm Buffer Kit (see <xref rid="sec9" ref-type="sec">key resources table</xref>).</p></list-item><list-item id="o0575"><label>22.</label><p id="p0685">Resuspend pellets in 80&#x000a0;&#x003bc;L Fix/Perm buffer and incubate for 30&#x000a0;min at RT in the dark.</p></list-item><list-item id="o0580"><label>23.</label><p id="p0690">Prepare 1&#x000d7; Perm buffer by diluting 1 part 10&#x000d7; Perm buffer from the FoxP3 Fix/Perm Buffer Kit (see <xref rid="sec9" ref-type="sec">key resources table</xref>) in 9 parts ddH<sub>2</sub>O.</p></list-item><list-item id="o0585"><label>24.</label><p id="p0695">Wash cells by adding 100&#x000a0;&#x003bc;L 1&#x000d7; Perm buffer to each well.</p></list-item><list-item id="o0590"><label>25.</label><p id="p0700">Centrifuge plate at 500&#x000a0;g for 5&#x000a0;min at RT and discard supernatant.</p></list-item></list>
<disp-quote><p><bold><italic>Note:</italic></bold> Cells are hardly visible after fixation.</p></disp-quote>
<list list-type="simple" id="olist0165"><list-item id="o0595"><label>26.</label><p id="p0705">Resuspend cells in 150&#x000a0;&#x003bc;L 1&#x000d7; Perm buffer and incubate for 5&#x000a0;min at RT in the dark.</p></list-item><list-item id="o0600"><label>27.</label><p id="p0710">Centrifuge plate at 500&#x000a0;g for 5&#x000a0;min at RT and discard supernatant.</p></list-item></list>
<disp-quote><p><inline-graphic xlink:href="fx4.gif"/><bold>Pause point:</bold> If cells cannot be analyzed on the same day, resuspend cells in 1&#x000d7; Perm Buffer and store O/N on 4&#x000b0;C in the dark. Resume with intracellular staining on the next day.</p></disp-quote>
<list list-type="simple" id="olist0170"><list-item id="o0605"><label>28.</label><p id="p0715">Prepare the intracellular antibody staining mix (according to table in <xref rid="sec2" ref-type="sec">materials and equipment</xref>) in 1&#x000d7; Perm Buffer.</p></list-item><list-item id="o0610"><label>29.</label><p id="p0720">Resuspend cells in 10&#x000a0;&#x003bc;L intracellular antibody staining mix and incubate for 30&#x000a0;min at RT in the dark.</p></list-item></list>
<disp-quote><p><bold><italic>Note:</italic></bold> For staining of nuclear antigens such as FoxP3, always include an isotype control.</p></disp-quote>
<list list-type="simple" id="olist0175"><list-item id="o0615"><label>30.</label><p id="p0725">Wash cells by adding 150&#x000a0;&#x003bc;L 1&#x000d7; Perm buffer.</p></list-item><list-item id="o0620"><label>31.</label><p id="p0730">Centrifuge plate at 500&#x000a0;g for 5&#x000a0;min at RT and discard supernatant.</p></list-item><list-item id="o0625"><label>32.</label><p id="p0735">Resuspend cells in 150&#x000a0;&#x003bc;L 1% FCS/PBS.</p></list-item><list-item id="o0630"><label>33.</label><p id="p0740">Acquire samples on FACS machine.<list list-type="simple" id="olist0180"><list-item id="o0635"><label>a.</label><p id="p0745">We used a Cytoflex S flow cytometer (Beckman Coulter) for our studies and analyzed the data using CytExpert and FlowJo.</p></list-item></list></p></list-item></list>
</p></sec></sec><sec id="sec4"><title>Expected outcomes</title><p id="p0750">Fully differentiated, MOG<sub>35&#x02013;55</sub> loaded BM-DCs should be viable and exhibit clear baseline CD80, CD86, MHCII, MHCI surface expression (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>). Additionally, quality control of DCs can be extended to fully characterize the expression patterns of co-inhibitory vs. co-stimulatory receptors of the transferred DCs. These markers can include but are not limited to PD-L1, PD-L2, CD85k, Gal9 or HVME (<xref rid="bib7" ref-type="bibr">Vogel et&#x000a0;al., 2022</xref>).</p><p id="p0755">As shown in <xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>A, repeated adoptive transfer of MOG<sub>35&#x02013;55</sub> loaded DCs strongly ameliorates EAE severity as assessed by the course of clinical scores and weight loss. The improvement of EAE severity is accompanied by a significant increase in regulatory CD4<sup>+</sup>CD25<sup>+</sup>FoxP3<sup>+</sup> Tregs in the inguinal lymph node and spleen at 17&#x000a0;days post EAE induction (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>B). We also observed that the tolerogenic properties of DCs and their potential to induce Tregs can already be assessed 3&#x000a0;days after a single BM-DC transfer on day 7 post EAE induction (<xref rid="bib7" ref-type="bibr">Vogel et&#x000a0;al., 2022</xref>).<fig id="fig5"><label>Figure&#x000a0;5</label><caption><p>BM-DC transfer ameliorates EAE and induces Tregs</p><p>Clinical scores, weights, cumulative and maximum score of EAE-bearing mice after no DC transfer or the transfer of 500 000 MOG loaded BM-DCs (A)&#x000a0;and quantification of Tregs in spleen and lymph nodes 3&#x000a0;days after the last DC transfer (day 17). n&#x000a0;= 5&#x02013;6 per group (B). Data are represented as mean&#x000a0;&#x000b1; SEM of biologically independent animals. &#x02217;P&#x000a0;&#x0003c;&#x000a0;0.05, &#x02217;&#x02217;&#x02217;P&#x000a0;&#x0003c;&#x000a0;0.001, unpaired t-test.</p></caption><graphic xlink:href="gr5"/></fig></p></sec><sec id="sec5"><title>Quantification and statistical analysis</title><p id="p0760">Differences in clinical EAE scores and weight loss over the disease course serve as a main read-out for the tolerogenic potential of transferred DCs (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>A). Additionally, parameters such as cumulative score (summarizing each daily score to a total cumulative score), maximum disease score reached (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>A), or the day of onset/peak can be used to assess differences in disease kinetic or severity.</p><p id="p0765">For the analysis of Treg populations in the spleen and lymph nodes, a gating strategy as shown in <xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref> can be used. Flow cytometric gates for CD25<sup>+</sup>FoxP3<sup>+</sup>CD4<sup>+</sup> T&#x000a0;cells should be set based on FMO and isotype controls (<xref rid="fig7" ref-type="fig">Figure&#x000a0;7</xref>). Quantification of Tregs as percentage of CD4<sup>+</sup> or all CD3<sup>+</sup> T&#x000a0;cells allows the comparison of DC-mediated Treg induction between the experimental groups.<fig id="fig6"><label>Figure&#x000a0;6</label><caption><p>Flow cytometric analysis of splenic Tregs in the spleen 3&#x000a0;days after the last DC transfer</p></caption><graphic xlink:href="gr6"/></fig><fig id="fig7"><label>Figure&#x000a0;7</label><caption><p>Gating of CD25<sup>+</sup> T&#x000a0;cells and FoxP3<sup>+</sup> CD4<sup>+</sup> T&#x000a0;cells based on a FMO and isotype control</p></caption><graphic xlink:href="gr7"/></fig></p></sec><sec id="sec6"><title>Limitations</title><p id="p0770">Many variables including mouse gender, age, housing conditions (diet, temperature, microbiota), stress and pertussis potency/dosing strongly affect EAE onset and severity. Transferred BM-DC numbers, timing and quantity of adoptive cell transfers described in this protocol have been optimized for the EAE kinetics established in our laboratory and might need to be adapted.</p><p id="p0775">This protocol specifically focuses on the analysis and quantification of Tregs in response to the transfer of antigen loaded DCs. However, many other tolerogenic features of DCs such as cytokine production can account for observed effects and require additional read-outs.</p></sec><sec id="sec7"><title>Troubleshooting</title><sec id="sec7.1"><title>Problem 1</title><p id="p0780">Mice do not develop EAE or just show very low disease scores. (See step 2).</p></sec><sec id="sec7.2"><title>Potential solution</title><p id="p0785">
<list list-type="simple" id="ulist0015"><list-item id="u0030"><label>&#x02022;</label><p id="p0790">Increase dose of pertussis. Every new pertussis batch needs to be tested for its potency.</p></list-item><list-item id="u0035"><label>&#x02022;</label><p id="p0795">Stress significantly reduces EAE incidence and severity. Try to minimize stress of the animals as much as possible especially during the immunization period. If mice are moved to other rooms, let them rest for at least a week prior to EAE induction.</p></list-item><list-item id="u0040"><label>&#x02022;</label><p id="p0800">Always freshly prepare pertussis injection solution.</p></list-item><list-item id="u0045"><label>&#x02022;</label><p id="p0805">Only use freshly thawed MOG<sub>35&#x02013;55</sub> aliquots and keep always on ice.</p></list-item><list-item id="u0050"><label>&#x02022;</label><p id="p0810">Ensure proper injection technique. Failed s.c. and i.p. injections strongly interfere with EAE development.</p></list-item></list>
</p></sec><sec id="sec7.3"><title>Problem 2</title><p id="p0815">Bone marrow cells are not properly differentiated into DCs. (See step 8).</p></sec><sec id="sec7.4"><title>Potential solution</title><p id="p0820">
<list list-type="simple" id="ulist0020"><list-item id="u0055"><label>&#x02022;</label><p id="p0825">Assess the potency of GM-CSF and IL-4 by increasing their concentration. Avoid repeated freeze-thaw cycles of cytokines.</p></list-item><list-item id="u0060"><label>&#x02022;</label><p id="p0830">Test a different FCS batch.</p></list-item><list-item id="u0065"><label>&#x02022;</label><p id="p0835">Increase the number of seeded bone marrow cells at the start of differentiation to 1&#x000a0;&#x000d7;&#x000a0;10<sup>7</sup> in 10&#x000a0;mL.</p></list-item></list>
</p></sec><sec id="sec7.5"><title>Problem 3</title><p id="p0840">BM-DC Transfer does not ameliorate EAE severity. (See steps 11 and 12).</p></sec><sec id="sec7.6"><title>Potential solution</title><p id="p0845">
<list list-type="simple" id="ulist0025"><list-item id="u0070"><label>&#x02022;</label><p id="p0850">Check viability and expression of quality control markers of BM-DCs after MOG<sub>35&#x02013;55</sub> loading.</p></list-item><list-item id="u0075"><label>&#x02022;</label><p id="p0855">Increase MOG<sub>35&#x02013;55</sub> concentration.</p></list-item><list-item id="u0080"><label>&#x02022;</label><p id="p0860">Increase BM-DC numbers transferred.</p></list-item><list-item id="u0085"><label>&#x02022;</label><p id="p0865">Depending on EAE onset and severity, timepoints of BM-DC transfers can be changed.</p></list-item><list-item id="u0090"><label>&#x02022;</label><p id="p0870">Ensure proper intravenous injection technique.</p></list-item></list>
</p></sec><sec id="sec7.7"><title>Problem 4</title><p id="p0875">BM-DC transfer does not increase abundance of CD25<sup>+</sup>FoxP3<sup>+</sup>CD4<sup>+</sup> T&#x000a0;cell population.</p></sec><sec id="sec7.8"><title>Potential solution</title><p id="p0880">We noticed that the appropriate timepoint of harvest and the location (spleen or lymph node) are critical to observe the described effect.</p></sec><sec id="sec7.9"><title>Problem 5</title><p id="p0885">Problems with flow cytometric analysis and/or proper gating of T&#x000a0;cell populations and Tregs.</p></sec><sec id="sec7.10"><title>Potential solution</title><p id="p0890">
<list list-type="simple" id="ulist0030"><list-item id="u0095"><label>&#x02022;</label><p id="p0895">Titrate correct dilution of antibody to get the best signal resolution.</p></list-item><list-item id="u0100"><label>&#x02022;</label><p id="p0900">Check if compensation is correct.</p></list-item><list-item id="u0105"><label>&#x02022;</label><p id="p0905">If isotype or FMO controls exhibit signal and thereby indicate high unspecific binding, increase washing steps after antibody staining or add an additional Fc blocking step (e.g., with TruStain FcX&#x02122;, BioLegend, Cat# 101319) prior to the surface staining.</p></list-item></list>
</p></sec></sec><sec id="sec8"><title>Resource availability</title><sec id="sec8.1"><title>Lead contact</title><p id="p0910">Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Omar Sharif (<ext-link ext-link-type="uri" xlink:href="mailto:omar.sharif@meduniwien.ac.at" id="intref0010">omar.sharif@meduniwien.ac.at</ext-link>).</p></sec><sec id="sec8.2"><title>Materials availability</title><p id="p0915">This study did not generate new unique reagents.</p></sec></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Barthelmes</surname><given-names>J.</given-names></name><name><surname>Tafferner</surname><given-names>N.</given-names></name><name><surname>Kurz</surname><given-names>J.</given-names></name><name><surname>De Bruin</surname><given-names>N.</given-names></name><name><surname>Parnham</surname><given-names>M.J.</given-names></name><name><surname>Geisslinger</surname><given-names>G.</given-names></name><name><surname>Schiffmann</surname><given-names>S.</given-names></name></person-group><article-title>Induction of experimental autoimmune encephalomyelitis in mice and evaluation of the disease-dependent distribution of immune cells in various tissues</article-title><source>J.&#x000a0;Vis. Exp.</source><year>2016</year><fpage>53933</fpage></element-citation></ref><ref id="bib2"><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Benedek</surname><given-names>G.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Bodhankar</surname><given-names>S.</given-names></name><name><surname>Nguyen</surname><given-names>H.</given-names></name><name><surname>Kent</surname><given-names>G.</given-names></name><name><surname>Jordan</surname><given-names>K.</given-names></name><name><surname>Manning</surname><given-names>D.</given-names></name><name><surname>Vandenbark</surname><given-names>A.A.</given-names></name><name><surname>Offner</surname><given-names>H.</given-names></name></person-group><article-title>Estrogen induces multiple regulatory B cell subtypes and promotes M2 microglia and neuroprotection during experimental autoimmune encephalomyelitis</article-title><source>J.&#x000a0;Neuroimmunol.</source><volume>293</volume><year>2016</year><fpage>45</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">27049561</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Croxford</surname><given-names>A.L.</given-names></name><name><surname>Kurschus</surname><given-names>F.C.</given-names></name><name><surname>Waisman</surname><given-names>A.</given-names></name></person-group><article-title>Mouse models for multiple sclerosis: historical facts and future implications</article-title><source>Biochim. Biophys. Acta</source><volume>1812</volume><year>2011</year><fpage>177</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">20600870</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Helft</surname><given-names>J.</given-names></name><name><surname>B&#x000f6;ttcher</surname><given-names>J.</given-names></name><name><surname>Chakravarty</surname><given-names>P.</given-names></name><name><surname>Zelenay</surname><given-names>S.</given-names></name><name><surname>Huotari</surname><given-names>J.</given-names></name><name><surname>Schraml</surname><given-names>B.U.</given-names></name><name><surname>Goubau</surname><given-names>D.</given-names></name><name><surname>Reis E Sousa</surname><given-names>C.</given-names></name></person-group><article-title>GM-CSF mouse bone&#x000a0;marrow cultures comprise a heterogeneous population of CD11c(+)MHCII(+) macrophages and dendritic cells</article-title><source>Immunity</source><volume>42</volume><year>2015</year><fpage>1197</fpage><lpage>1211</lpage><pub-id pub-id-type="pmid">26084029</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Mendel</surname><given-names>I.</given-names></name><name><surname>Kerlero De Rosbo</surname><given-names>N.</given-names></name><name><surname>Ben-Nun</surname><given-names>A.</given-names></name></person-group><article-title>A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T&#x000a0;cell receptor V beta expression of encephalitogenic T&#x000a0;cells</article-title><source>Eur. J. Immunol.</source><volume>25</volume><year>1995</year><fpage>1951</fpage><lpage>1959</lpage><pub-id pub-id-type="pmid">7621871</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Rahn</surname><given-names>E.J.</given-names></name><name><surname>Iannitti</surname><given-names>T.</given-names></name><name><surname>Donahue</surname><given-names>R.R.</given-names></name><name><surname>Taylor</surname><given-names>B.K.</given-names></name></person-group><article-title>Sex differences in a mouse model of multiple sclerosis: neuropathic pain behavior in females but not males and protection from neurological deficits during proestrus</article-title><source>Biol. Sex Differ.</source><volume>5</volume><year>2014</year><fpage>4</fpage><pub-id pub-id-type="pmid">24581045</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Vogel</surname><given-names>A.</given-names></name><name><surname>Martin</surname><given-names>K.</given-names></name><name><surname>Soukup</surname><given-names>K.</given-names></name><name><surname>Halfmann</surname><given-names>A.</given-names></name><name><surname>Kerndl</surname><given-names>M.</given-names></name><name><surname>Brunner</surname><given-names>J.S.</given-names></name><name><surname>Hofmann</surname><given-names>M.</given-names></name><name><surname>Oberbichler</surname><given-names>L.</given-names></name><name><surname>Korosec</surname><given-names>A.</given-names></name><name><surname>Kuttke</surname><given-names>M.</given-names></name><etal/></person-group><article-title>JAK1 signaling in dendritic cells promotes peripheral tolerance in autoimmunity through PD-L1-mediated regulatory T&#x000a0;cell induction</article-title><source>Cell Rep.</source><volume>38</volume><year>2022</year><fpage>110420</fpage><pub-id pub-id-type="pmid">35196494</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Wiedrick</surname><given-names>J.</given-names></name><name><surname>Meza-Romero</surname><given-names>R.</given-names></name><name><surname>Gerstner</surname><given-names>G.</given-names></name><name><surname>Seifert</surname><given-names>H.</given-names></name><name><surname>Chaudhary</surname><given-names>P.</given-names></name><name><surname>Headrick</surname><given-names>A.</given-names></name><name><surname>Kent</surname><given-names>G.</given-names></name><name><surname>Maestas</surname><given-names>A.</given-names></name><name><surname>Offner</surname><given-names>H.</given-names></name><name><surname>Vandenbark</surname><given-names>A.A.</given-names></name></person-group><article-title>Sex differences in EAE reveal common&#x000a0;and distinct cellular and molecular&#x000a0;components</article-title><source>Cell. Immunol.</source><volume>359</volume><year>2021</year><fpage>104242</fpage><pub-id pub-id-type="pmid">33190849</pub-id></element-citation></ref></ref-list><sec sec-type="data-availability" id="da0010"><title>Data and code availability</title><p id="p0030">This study did not generate/analyze any datasets or code.</p></sec><ack id="ack0010"><title>Acknowledgments</title><p id="p0925">The graphical abstract and <xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref> were created by using <ext-link ext-link-type="uri" xlink:href="http://BioRender.com" id="intref0080">BioRender.com</ext-link>. This work was supported by the <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100002428</institution-id><institution>FWF</institution></institution-wrap></funding-source> 31106 (to G.S.) and 31568 (to O.S.), the <funding-source id="gs2">Christian Doppler Laboratory</funding-source> for Arginine Metabolism in Rheumatoid Arthritis and Multiple Sclerosis (to G.S.), and a DOC fellowship of the Austrian Academy of Sciences (to A.V.).</p><sec id="sec10"><title>Author contributions</title><p id="p0930">Methodology: A.V..; data acquisition and analysis: A.V.; writing: A.V. and O.S.; figure&#x000a0;and video generation: A.V. and M.K.; funding and supervision: G.S. and O.S. All authors reviewed, edited, and approved the final manuscript.</p></sec><sec sec-type="COI-statement" id="sec11"><title>Declaration of interests</title><p id="p0935">The authors declare no competing interests.</p></sec></ack><fn-group><fn id="appsec1" fn-type="supplementary-material"><p id="p0940">Supplemental information can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.xpro.2022.101653" id="intref0085">https://doi.org/10.1016/j.xpro.2022.101653</ext-link>.</p></fn></fn-group></back></article>
